🇺🇸 FDA
Pipeline program

An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients

D853AC00001

Phase 1 other active

Quick answer

An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients for Breast Cancer is a Phase 1 program (other) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Breast Cancer
Phase
Phase 1
Modality
other
Status
active

Clinical trials